US M&A and equity raisings

3,392 deals since January 2025, with sources and adviser credits where available · as at 20 Nov 2026 · Venture rounds

Deals dated after 30 September 2026 are still being collected.

Deal size
Custom range

62 deals · US$14bndisclosed · Biotech · Clear

Columns
US M&A deals and equity raisings
Date Target Vendor Acquirer Type Status Value US$m Sector Advisers
Dec 2025 Apimeds Pharmaceuticals US ––ConvertibleCompleted10.9Pharma+1 Nelson Mullins Riley & Scarborough (issuer)EF Hutton (lead manager)
Jan 2026 Aktis Oncology ––IPOListed317.7Biotech+2 Paul Hastings (issuer)Goodwin (issuer)J.P. Morgan (lead manager)BofA Securities (lead manager)Leerink Partners (lead manager)TD Securities (lead manager)Davis Polk (lead manager)
Jan 2026 Polaryx Therapeutics ––Direct listingCompleted–Biotech+1 Maxim Group (issuer)Gibson Dunn (issuer)Brownstein Hyatt Farber Schreck (issuer)
Feb 2026 Perspective Therapeutics ––Follow-on offeringAnnounced175.0Radiopharmaceuticals+2 Piper Sandler (lead manager)UBS (lead manager)Oppenheimer & Co. (lead manager)Truist Securities (lead manager)LifeSci Capital (lead manager)
Feb 2026 Veradermics ––IPOAnnounced256.3Dermatology+2 Ropes & Gray (issuer)Jefferies (lead manager)Leerink Partners (lead manager)Citi (lead manager)Cantor Fitzgerald (lead manager)Cooley (lead manager)
Feb 2026 Eikon Therapeutics ––IPOAnnounced381.2Oncology+1 Covington & Burling (issuer)J.P. Morgan (lead manager)Morgan Stanley (lead manager)BofA Securities (lead manager)Cantor Fitzgerald (lead manager)Mizuho Securities (lead manager)Davis Polk (lead manager)
Feb 2026 Agomab Therapeutics NV ––IPOAnnounced200.0Biotech+2 Goodwin (issuer)Baker McKenzie (issuer)J.P. Morgan (lead manager)Morgan Stanley (lead manager)Leerink Partners (lead manager)Van Lanschot Kempen (lead manager)Davis Polk (lead manager)Clifford Chance (lead manager)
Feb 2026 Liminatus Pharma ––Follow-on offeringAnnounced4.0Biotech+2 Loeb & Loeb (issuer)Maxim Group (lead manager)Lucosky Brookman (lead manager)
Feb 2026 Sensei Biotherapeutics ––PlacementPending200.0Biotech+2 Cantor Fitzgerald (issuer)Citi (issuer)Sidley Austin (issuer)Leerink Partners (lead manager)
Feb 2026 Generate Biomedicines ––IPOListed400.0Biotech+2 Goodwin (issuer)Goldman Sachs (lead manager)Morgan Stanley (lead manager)Piper Sandler (lead manager)Guggenheim Securities (lead manager)Cantor Fitzgerald (lead manager)Latham & Watkins (lead manager)
Mar 2026 Candid Therapeutics ––PlacementPending505.0Biotech+1 Cooley (issuer)Jefferies (lead manager)BofA Securities (lead manager)TD Securities (lead manager)Cantor Fitzgerald (lead manager)Latham & Watkins (lead manager)
Mar 2026 Pulmatrix ––PlacementAnnounced19.0Biotech Palladium Capital Group (lead manager)
Apr 2026 Korsana Biosciences ––PlacementAnnounced380.0Biotech+1 Cooley (lead manager)
Apr 2026 Obsidian Therapeutics ––PlacementCompleted350.0Biotech+2 GoodwinSidley Austin (issuer)Leerink Partners (lead manager)TD Securities (lead manager)Piper Sandler (lead manager)William Blair (lead manager)LifeSci Capital (lead manager)Mintz (lead manager)
Apr 2026 Kailera Therapeutics ––IPOAnnounced625.0Biotech+1 Latham & Watkins (issuer)William Blair (lead manager)J.P. Morgan (lead manager)Jefferies (lead manager)Leerink Partners (lead manager)TD Securities (lead manager)Evercore (lead manager)Paul Hastings (lead manager)
Apr 2026 Opus Genetics ––PlacementAnnounced5.0Biotech+1 Sidley Austin (issuer)
Apr 2026 Avalyn Pharma ––IPOListed300.0Biotech+2 Goodwin (issuer)Morgan Stanley (lead manager)Jefferies (lead manager)Evercore (lead manager)Guggenheim Securities (lead manager)Davis Polk (lead manager)
Apr 2026 Hemab Therapeutics Holdings ––IPOAnnounced301.5Biotech+1 WilmerHale (issuer)Goldman Sachs (lead manager)Jefferies (lead manager)Evercore (lead manager)Wedbush Securities (lead manager)Goodwin (lead manager)
Apr 2026 Seaport Therapeutics ––IPOAnnounced254.9Biotech+1 Goodwin (issuer)Goldman Sachs (lead manager)J.P. Morgan (lead manager)Leerink Partners (lead manager)Citi (lead manager)Stifel (lead manager)Latham & Watkins (lead manager)
May 2026 Odyssey Therapeutics ––IPOAnnounced279.0Biotech+1 Covington & Burling (issuer)J.P. Morgan (lead manager)TD Securities (lead manager)Cantor Fitzgerald (lead manager)Wedbush Securities (lead manager)Oppenheimer & Co. (lead manager)Cooley (lead manager)
May 2026 Odyssey Therapeutics ––PlacementPending25.0Biotech+1 J.P. Morgan (lead manager)TD Securities (lead manager)Cantor Fitzgerald (lead manager)Wedbush Securities (lead manager)Oppenheimer & Co. (lead manager)Cooley (lead manager)
May 2026 Quince Therapeutics ––PlacementAnnounced115.0Biotech+2 EvercoreCantor FitzgeraldLifeSci Capital (lead manager)Gibson Dunn (lead manager)
May 2026 Mentari Therapeutics ––PlacementAnnounced290.0Biotech+1 Gibson Dunn (issuer)Cooley (lead manager)Jefferies (lead manager)TD Securities (lead manager)Stifel (lead manager)Guggenheim Securities (lead manager)Wedbush Securities (lead manager)
May 2026 Optimi Health Corp. ––Follow-on offeringAnnounced15.0Biotech+2 Norton Rose Fulbright (issuer)Joseph Gunnar & Co. (lead manager)Cozen O'Connor (lead manager)
Jun 2026 Avenzo Therapeutics ––PlacementPending215.0Biotech+2 Leerink Partners (lead manager)Goldman Sachs (lead manager)Piper Sandler (lead manager)Guggenheim Securities (lead manager)Mintz (lead manager)
Jun 2026 Parabilis Medicines ––IPOListed670.0Biotech+2 Goodwin (issuer)Leerink Partners (lead manager)BofA Securities (lead manager)Evercore (lead manager)Guggenheim Securities (lead manager)LifeSci Capital (lead manager)Covington & Burling (lead manager)
Jun 2026 Adial Pharmaceuticals ––PlacementPending32.0Biotech+1 TD Securities (issuer)Lucid Capital Markets (lead manager)
Jun 2026 Parabilis Medicines ––PlacementCompleted75.0Biotech+1 Goodwin (issuer)
Jun 2026 Kardigan ––IPOListed400.0Biotech+2 Goodwin (issuer)J.P. Morgan (lead manager)Jefferies (lead manager)Leerink Partners (lead manager)TD Securities (lead manager)Latham & Watkins (lead manager)
Jun 2026 Remix Therapeutics ––PlacementPending100.0Biotech+2 Goldman Sachs (lead manager)Jefferies (lead manager)Evercore (lead manager)Cooley (lead manager)
Jun 2026 JATT II Acquisition Corp ––PlacementAnnounced225.0Biotech+1 Guggenheim Securities (lead manager)Cantor Fitzgerald (lead manager)LifeSci Capital (lead manager)Davis Polk (lead manager)
Jul 2026 BridgeBio Pharma ––PlacementAnnounced1,000.0Biotech+1 EvercoreSullivan & CromwellMintzGibson DunnLatham & Watkins (issuer)
Jul 2026 Avere Therapeutics ––PlacementAnnounced320.0Biotech+1 Sullivan & CromwellGibson Dunn (issuer)Cooley (lead manager)Jefferies (lead manager)Wedbush Securities (lead manager)
Jul 2026 Jasper Therapeutics ––PlacementAnnounced132.0Biotech+1 Piper Sandler (lead manager)LifeSci Capital (lead manager)
Jul 2026 Codexis ––Follow-on offeringCompleted–Biotech+1 Piper Sandler (lead manager)
Jul 2026 Scribe Therapeutics ––IPOListed128.7Biotech+1 Fenwick & West (issuer)Leerink Partners (lead manager)Goldman Sachs (lead manager)Guggenheim Securities (lead manager)Wells Fargo Securities (lead manager)Latham & Watkins (lead manager)
Jul 2026 Research Alliance Corporation III ––PlacementAnnounced100.0Biotech+2 Leerink Partners (lead manager)UBS (lead manager)Wells Fargo Securities (lead manager)LifeSci Capital (lead manager)Kirkland & Ellis (lead manager)
Jul 2026 Caldera Therapeutics ––PlacementAnnounced278.0Biotech+1 Jefferies (lead manager)TD Securities (lead manager)Guggenheim Securities (lead manager)UBS (lead manager)LifeSci Capital (lead manager)Cooley (lead manager)
Jul 2026 Inovio Pharmaceuticals ––Follow-on offeringCompleted–Biotech+1 Piper Sandler (issuer)
Jul 2026 Processa Pharmaceuticals ––PlacementAnnounced200.0Biotech+1 Leerink Partners (lead manager)Evercore (lead manager)UBS (lead manager)Wells Fargo Securities (lead manager)Mintz (lead manager)
Jul 2026 Apnimed ––IPOListed192.0Biotech+1 Goodwin (issuer)BofA Securities (lead manager)Evercore (lead manager)Cantor Fitzgerald (lead manager)LifeSci Capital (lead manager)Cleary Gottlieb Steen & Hamilton (lead manager)
Aug 2026 BlossomHill Therapeutics ––IPOListed150.0Biotech+2 Cooley (issuer)J.P. Morgan (lead manager)Leerink Partners (lead manager)Guggenheim Securities (lead manager)LifeSci Capital (lead manager)H.C. Wainwright & Co. (lead manager)Latham & Watkins (lead manager)
Aug 2026 Latigo Biotherapeutics ––IPOListed345.6Biotech+2 Cooley (issuer)Goldman Sachs (lead manager)Jefferies (lead manager)Leerink Partners (lead manager)Guggenheim Securities (lead manager)Latham & Watkins (lead manager)
Aug 2026 Attovia Therapeutics ––IPOListed289.0Biotech+1 Fenwick & West (issuer)Morgan Stanley (lead manager)Leerink Partners (lead manager)Citi (lead manager)RBC Capital Markets (lead manager)LifeSci Capital (lead manager)Cooley (lead manager)
Aug 2026 Braveheart Bio ––IPOListed382.5Biotech+2 Goodwin (issuer)Goldman Sachs (lead manager)Jefferies (lead manager)TD Securities (lead manager)Stifel (lead manager)Cantor Fitzgerald (lead manager)Covington & Burling (lead manager)
Aug 2026 Ensysce Biosciences ––PlacementAnnounced43.0Biotech+1 Cantor Fitzgerald (lead manager)UBS (lead manager)Mintz (lead manager)
Aug 2026 Skye Bioscience ––PlacementAnnounced68.0Biotech+1 Leerink Partners (lead manager)MTS Health Partners (lead manager)Mintz (lead manager)
Aug 2026 Silence Therapeutics ––PlacementCompleted201.0Biotech+1 Goodwin (lead manager)Jefferies (lead manager)Morgan Stanley (lead manager)Cantor Fitzgerald (lead manager)William Blair (lead manager)
Aug 2026 Slate Medicines ––PlacementAnnounced245.0Biotech+1 Cooley (issuer)
Aug 2026 Ambros Therapeutics ––PlacementAnnounced150.0Biotech+1 Cooley (issuer)

Deals come from SEC filings (merger proxies, tender offers, 8-K announcements and IPO prospectuses), the deal pages and transaction lists of law firms and banks, companies' press releases and the press. How the data is built